Tolerating a low level of transmission just might be the better strategy
The figure is a subset, not covering huge expense of extended patents on high-priced biologics like Humira
A model vastly outperforms predictions based on prior hospital data
Management and real estate deals to owners’ firms siphon off most profits
Nudges already proven to work in the real-world increased uptake of COVID-19 boosters; nudges based on lab findings and expert insights, not so much
In LA, doctors who lose a patient to opioid overdose get a letter from the coroner; tweaking that letter had a substantial impact
The shift lends credibility to medicines vs. trials that exclude people 65 and older
Years after a paper goes unpublished, it’s fodder for a major Federal Trade Commission proposal
U.S. efforts to encourage transparency widely ignored by companies
An upfront fee for taking Medicaid patients could shorten stays
The ethics of asking brain surgery patients to allow unrelated research while on the operating table
Getting the mix right is the goal of a Medicare pilot, which itself could use substantial improvement
Tying payments to weight, rather than behaviors, marginally more effective
Dedicated FDA staff guide companies during design of clinical trials
Pharma companies less likely to disclose critical drug information than public institutions
Nudge to improve preventive medicine performance didn’t work – and yielded discontent